Title: "Significant Activity" for ADC in Ovarian Cancer. Cord-id: klx5zfy5 Document date: 2021_6_17
ID: klx5zfy5
Snippet: Mirvetuximab soravtansine plus bevacizumab may benefit women with recurrent ovarian cancer and high folate receptor alpha (FRα) expression, regardless of platinum sensitivity. In a phase I/II trial, the combination elicited an objective response rate of 64% and a median progression-free survival of 10.6 months in patients with FRα-high tumors.
Document: Mirvetuximab soravtansine plus bevacizumab may benefit women with recurrent ovarian cancer and high folate receptor alpha (FRα) expression, regardless of platinum sensitivity. In a phase I/II trial, the combination elicited an objective response rate of 64% and a median progression-free survival of 10.6 months in patients with FRα-high tumors.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date